1107 related articles for article (PubMed ID: 26088896)
1. Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel.
Montouris G; Yang H; Williams B; Zhou S; Laurenza A; Fain R
Epilepsy Res; 2015 Aug; 114():131-40. PubMed ID: 26088896
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study.
Rosenfeld W; Conry J; Lagae L; Rozentals G; Yang H; Fain R; Williams B; Kumar D; Zhu J; Laurenza A
Eur J Paediatr Neurol; 2015 Jul; 19(4):435-45. PubMed ID: 25823975
[TBL] [Abstract][Full Text] [Related]
3. Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307.
Krauss GL; Perucca E; Ben-Menachem E; Kwan P; Shih JJ; Squillacote D; Yang H; Gee M; Zhu J; Laurenza A
Epilepsia; 2013 Jan; 54(1):126-34. PubMed ID: 22905878
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305.
French JA; Krauss GL; Steinhoff BJ; Squillacote D; Yang H; Kumar D; Laurenza A
Epilepsia; 2013 Jan; 54(1):117-25. PubMed ID: 22905857
[TBL] [Abstract][Full Text] [Related]
5. [Perampanel in treatment of refractory partial epilepsy in adolescents and adults: results of international multicenter randomized, double-blind, placebo-controlled phase III studies].
Belousova ED
Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(8):32-8. PubMed ID: 25345628
[TBL] [Abstract][Full Text] [Related]
6. Perampanel for adjunctive treatment of partial-onset seizures: a pooled dose-response analysis of phase III studies.
Kramer LD; Satlin A; Krauss GL; French J; Perucca E; Ben-Menachem E; Kwan P; Shih JJ; Laurenza A; Yang H; Zhu J; Squillacote D
Epilepsia; 2014 Mar; 55(3):423-31. PubMed ID: 24605793
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies.
Steinhoff BJ; Ben-Menachem E; Ryvlin P; Shorvon S; Kramer L; Satlin A; Squillacote D; Yang H; Zhu J; Laurenza A
Epilepsia; 2013 Aug; 54(8):1481-9. PubMed ID: 23663001
[TBL] [Abstract][Full Text] [Related]
8. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial.
Biton V; Berkovic SF; Abou-Khalil B; Sperling MR; Johnson ME; Lu S
Epilepsia; 2014 Jan; 55(1):57-66. PubMed ID: 24446953
[TBL] [Abstract][Full Text] [Related]
9. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial.
Ryvlin P; Werhahn KJ; Blaszczyk B; Johnson ME; Lu S
Epilepsia; 2014 Jan; 55(1):47-56. PubMed ID: 24256083
[TBL] [Abstract][Full Text] [Related]
10. Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307.
Krauss GL; Perucca E; Kwan P; Ben-Menachem E; Wang XF; Shih JJ; Patten A; Yang H; Williams B; Laurenza A
Epilepsia; 2018 Apr; 59(4):866-876. PubMed ID: 29574701
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures.
Krauss GL; Serratosa JM; Villanueva V; Endziniene M; Hong Z; French J; Yang H; Squillacote D; Edwards HB; Zhu J; Laurenza A
Neurology; 2012 May; 78(18):1408-15. PubMed ID: 22517103
[TBL] [Abstract][Full Text] [Related]
12. Long-term effects of adjunctive perampanel on cognition in adolescents with partial seizures.
Piña-Garza JE; Lagae L; Villanueva V; Renfroe JB; Laurenza A; Williams B; Kumar D; Meador KJ
Epilepsy Behav; 2018 Jun; 83():50-58. PubMed ID: 29653338
[TBL] [Abstract][Full Text] [Related]
13. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures.
Gidal BE; Ferry J; Majid O; Hussein Z
Epilepsia; 2013 Aug; 54(8):1490-7. PubMed ID: 23772853
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307.
Krauss GL; Perucca E; Ben-Menachem E; Kwan P; Shih JJ; Clément JF; Wang X; Bagul M; Gee M; Zhu J; Squillacote D
Epilepsia; 2014 Jul; 55(7):1058-68. PubMed ID: 24867391
[TBL] [Abstract][Full Text] [Related]
15. Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial.
Kwan P; Trinka E; Van Paesschen W; Rektor I; Johnson ME; Lu S
Epilepsia; 2014 Jan; 55(1):38-46. PubMed ID: 24116853
[TBL] [Abstract][Full Text] [Related]
16. Adjunctive perampanel in partial-onset seizures: Asia-Pacific, randomized phase III study.
Nishida T; Lee SK; Inoue Y; Saeki K; Ishikawa K; Kaneko S
Acta Neurol Scand; 2018 Apr; 137(4):392-399. PubMed ID: 29250772
[TBL] [Abstract][Full Text] [Related]
17. Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials.
Yang H; Laurenza A; Williams B; Patten A; Hussein Z; Ferry J
Epilepsy Res; 2015 Aug; 114():122-30. PubMed ID: 26088895
[TBL] [Abstract][Full Text] [Related]
18. Absence of Liver Toxicity in Perampanel-Treated Subjects: Pooled results from partial seizure phase III perampanel clinical studies.
Laurenza A; Yang H; Williams B; Zhou S; Ferry J
Epilepsy Res; 2015 Jul; 113():76-85. PubMed ID: 25986193
[TBL] [Abstract][Full Text] [Related]
19. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304.
French JA; Krauss GL; Biton V; Squillacote D; Yang H; Laurenza A; Kumar D; Rogawski MA
Neurology; 2012 Aug; 79(6):589-96. PubMed ID: 22843280
[TBL] [Abstract][Full Text] [Related]
20. Perampanel in the treatment of partial seizures: Time to onset and duration of most common adverse events from pooled Phase III and extension studies.
Ko D; Yang H; Williams B; Xing D; Laurenza A
Epilepsy Behav; 2015 Jul; 48():45-52. PubMed ID: 26057204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]